Point72 Asia Singapore Pte. Ltd. Takes $27,000 Position in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

Point72 Asia Singapore Pte. Ltd. bought a new position in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 18,027 shares of the company’s stock, valued at approximately $27,000.

Other institutional investors have also recently bought and sold shares of the company. Pale Fire Capital SE raised its stake in shares of Reneo Pharmaceuticals by 102.7% in the 4th quarter. Pale Fire Capital SE now owns 30,100 shares of the company’s stock valued at $48,000 after buying an additional 15,249 shares in the last quarter. Marquette Asset Management LLC bought a new stake in Reneo Pharmaceuticals in the first quarter valued at about $122,000. Vestal Point Capital LP bought a new stake in Reneo Pharmaceuticals in the fourth quarter valued at about $640,000. Finally, Highbridge Capital Management LLC raised its position in Reneo Pharmaceuticals by 6.5% in the second quarter. Highbridge Capital Management LLC now owns 2,915,376 shares of the company’s stock worth $4,402,000 after purchasing an additional 178,806 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Insider Buying and Selling at Reneo Pharmaceuticals

In other news, major shareholder Braden Michael Leonard bought 55,300 shares of Reneo Pharmaceuticals stock in a transaction dated Tuesday, September 17th. The shares were bought at an average price of $1.36 per share, for a total transaction of $75,208.00. Following the purchase, the insider now owns 3,358,243 shares of the company’s stock, valued at $4,567,210.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders purchased 256,239 shares of company stock valued at $355,105. 17.90% of the stock is currently owned by company insiders.

Reneo Pharmaceuticals Stock Performance

Shares of RPHM opened at $1.71 on Wednesday. Reneo Pharmaceuticals, Inc. has a 12 month low of $0.98 and a 12 month high of $9.21. The company has a 50-day moving average price of $1.48 and a two-hundred day moving average price of $1.59.

Reneo Pharmaceuticals (NASDAQ:RPHM) last posted its earnings results on Tuesday, August 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. Analysts expect that Reneo Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.

Reneo Pharmaceuticals Company Profile

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.